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ABSTRACT 
 
 
 This Interactive Qualifying Project (IQP) examined the controversial topic of transgenic 
animals, and described its effects on society.  The first two chapters focused on the technology 
itself, describing how transgenic animals are created and screened, and categorized the 
transgenic animals made to date.  The last two chapters went beyond the technology to 
investigate the ethics, as well as legal and regulatory issues surrounding the controversy.  Based 
on the research performed for this project, the authors concluded that most types of transgenic 
experiments should be continued, provided that IACUC and FDA supervision continues to 
balance the animals suffering with reasonable societal needs.  Patenting of transgenic animals 
has the potential to provide incentives to perform this type of research, however the current 
system is lacking. 
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PROJECT OBJECTIVES 
 
 
The objective of this project was to examine the topic of transgenic animals, and to 
discuss the effect of this controversial new technology on society.  The ability to create 
transgenic animals has come from a long history of scientific progress, chapter-1 explains what 
transgenic animals are and what methods exist to create them, while chapter-2 goes further and 
documents and categorizes the types of transgenic animals created to date, and describes their 
benefits to society.  As transgenic research has expanded quickly, new moral and ethical 
questions have been brought to light, so chapter-3 examines the ethics surrounding this 
controversial technology, and chapter-4 examines the legal and regulatory landscape, including 
the idea that animals are patentable.  The result of this project should be that the reader is 
informed of the key relevant information surrounding the transgenic debate, so they will be able 
to draw their own conclusions.  The authors will also present a researched opinion at the end of 
the report. 
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CHAPTER-1:  TRANSGENIC ANIMAL TECHNOLOGY 
John Raymond Martin 
An animal that is transgenic has been intentionally altered at the genomic level to include 
foreign DNA.  These changes create organisms that would never have existed in nature, and 
allow scientists new tools for conducting research and finding solutions to many of the world‟s 
greatest problems.  This first chapter will focus on the major transgenic techniques which include 
manipulation of a male pronucleus in a newly fertilized egg, and the manipulation of embryonic 
stem cells.  The efficiency of these methods is not very high, so additional techniques for 
selecting positive transgenic organisms that have cloned correctly will be discussed as well. 
 
BIOLOGY’S CENTRAL DOGMA 
 The main building blocks of life can be divided into three distinct molecules: DNA, 
RNA, and proteins.  DNA, or deoxyribonucleic acid, is the central repository of the genetic code.  
When an organism needs to make a compound, DNA is transcribed into RNA, or ribonucleic 
acid, which acts as an intermediary.  The RNA is free to travel from the nucleus to the cytoplasm 
where it is then transcribed into proteins which make up the bulk of the functional units of living 
organisms.  This one way progression of useful information from DNA to protein is called the 
central dogma and is essential to understanding transgenic animals. 
 The nucleic acids are made up of a phosphate and sugar backbone, and a coding core of 
base pairs (Figure 1).  This coding core matches purines: adenine (A) and guanine (G), with 
pyrimidines: cytosine (C), thymine (T), and uracil (U) to give the genomic code from which the 
organism eventually makes proteins.   
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The two halves of the DNA molecule are held together by hydrogen bonds between the 
base pairs (Figure 2).  Due to precise structural fits between the bases, only specific pairings 
occur: A with T or U, and C with G. When DNA is copied to either form new DNA, or is 
transcribed into RNA, these hydrogen bonds are broken and then reformed once copied.  The 
genetic information stored in the DNA, in the form of the order of the bases, is directly 
responsible for all of phenotypical traits observed as part of the organism.   
               
The idea that the phenotype or characteristics of an organism could be driven by some 
sort of genotype that was affected by mating was first observed by Gregor Mendel in the mid 
Figure 2: Hydrogen Bonding in DNA. The dashed 
lines between key hydrogen and oxygen residues show 
the hydrogen bonds between purine-pyrimidine base 
pairs (Farthalla et al., 2009). 
Figure 1: Structure of DNA.  The left shows the 
double helix nature of DNA, and the right shows the 
various components. (Human Genome, 2010) 
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19th century.  His experiments with peas led him to make two conclusions; first that during 
gamete formation the allele pairs separate, and second that this segregation of alleles is 
independent for every allele (Mendel, 1866).  This laid the groundwork for further study into 
genetics, such as that published by Watson and Crick showing that DNA has the chemical 
properties that Mendel laid out for genetic information.  They showed that the structure of DNA 
was such that it would follow a semi-conservation mechanism of replication that Mendel and 
others after him had predicted (Watson and Crick, 1953).  However, it was not until techniques 
for manipulating DNA were discovered that the advent of transgenic animals could come to 
fruition. 
 
RECOMBINANT DNA 
The recombination of DNA involves using several methods to rearrange, add, delete, or 
edit a section of DNA making it recombinant (rDNA).  This rDNA can then be inserted into an 
animal and expressed in vivo as if it were the animal‟s own DNA, giving the animal new 
properties.  The procedure generally uses restriction enzymes to cut sections of DNA, and DNA 
ligase an enzyme that can seal the DNA back together.  
 The ability to recombine DNAs from two different organisms was made possible by the 
work done on restriction enzymes in 1970; at last scientists could not only isolate and sequence 
DNA but also make changes to it.  Restriction enzymes make cuts to DNA at specific locations 
and in a specific way.  For example, the restriction enzyme EcoRI cuts at the sequence GAATTC 
(between the G and the A) to produce DNA fragments flanked by EcoRI sites.  And because the 
cut is not straight through both strands of the DNA molecule, it creates single-stranded “sticky 
ends” that can anneal to other DNA fragments cut with the same EcoRI enzyme.  Thus, DNAs 
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from different organisms cut by the same type of restriction enzyme will produce DNA 
fragments that can be annealed to each other, and then sealed by DNA ligase to produce rDNA.   
 
DNA CLONING 
 Once the rDNA has been formed, it then needs to be cloned to make large numbers of it, 
and inserted into a living cell.  With respect to DNA cloning, the newly created rDNA is usually 
inserted into a plasmid DNA or virus to amplify it, and to allow subsequent screening of 
successful positives.  Plasmids are circular DNAs normally found in bacteria (and some 
eukaryotic cells) that form high copy numbers in the cytoplasm.  rDNAs inserted into them also 
get replicated to high copy numbers. 
With respect to cloned DNA uptake, a number of techniques have been developed to 
allow this to happen efficiently with microbes, but when making a transgenic animal it is much 
harder to get a eukaryotic cell to uptake and express foreign DNA.  Both of the animal 
techniques discussed below in detail use microinjection of rDNA, the most reliable method; 
however there are other techniques that work as well to deliver the cloned DNA inside a cell, 
including using chemicals, electroporation, or viruses.  Chemicals such as calcium chloride or 
strontium chloride have been used for decades to allow bacteria to become competent to take up 
cloned DNAs.  For eukaryotic cells, delivery techniques often use a positively charged polymer 
which encapsulates the DNA, then binds to the cell surface and allows the DNA into the cell.  
Another method is electroporation which uses electricity to pull the DNA through the cell 
membrane.  Both of these methods rely on the fact that DNA is a negatively charged molecule 
because of its phosphate backbone.  Another method is the use of a virus, as was done by 
Jaenisch and Mintz (1974) to make the first transgenic animal.  This method uses the more 
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complex mechanism of a virus to infect cells to integrate their DNA to make a transgenic animal, 
and is the only method for creating transgenic animals after they have been born.  This makes 
viruses especially useful in gene therapy research. 
 
THE FIRST TRANSGENIC ORGANISMS 
The new rDNA and cloning technology lead to the creation of the first transgenic 
organism in 1973.  A group led by Stanley Cohen was able to add a gene to the bacterium E. coli 
from another bacterium (Cohen et al., 1973).  The creation of this first recombinant prokaryote 
was relatively simple compared to modern transgenesis of animals.  The first transgenic animal 
was a mouse created by Rudolf Jaenisch and Beatrice Mintz, which contained SV40 viral DNA 
sequences inserted into the mouse genome by microinjection into a blastocyst, although the 
rDNA was not expressed (Jaenisch and Mintz, 1973).   
In 1980, a new technique was developed to allow the microinjection of rDNA into the 
pronucleus of a newly fertilized egg (Gordon, 1980).  But again the rDNA was not expressed.  It 
was not until 1982 that a team would finally be able to express a rDNA gene of interest to 
produce a phenotypic change in a eukaryote, in this case a mouse (Palimiter et al., 1982).  In this 
experiment, the transgenic mouse, later dubbed supermouse, expressed growth hormone from 
another species, and grew larger than his non-transgenic littermates.   
Since this landmark experiment, research in this transgenic field has exploded, and most 
research facilities have thousands of transgenic animals to perform research on.  More recent 
techniques have also overcome some of the efficiency issues which earlier required many 
defective animals to be created.  With the technology now standardized, the emphasis has mostly 
shifted from creating transgenic animals to performing experiments on them. 
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TWO MAIN METHODS FOR CREATING TRANSGENIC ANIMALS 
 In order to create a transgenic animal, the altered rDNA must be inserted into the animal.  
There are two main approaches to this: pronuclear manipulation and embryonic stem cell 
manipulation, each of which has its own benefits and drawbacks which will be discussed. 
 
Approach 1: Pronuclear Manipulation 
One of the oldest and most widely used method for creating a transgenic animal is by 
manipulation of the male proucleus in a newly fertilized egg.  In order to do this, eggs are 
removed from a female which has typically been induced to super-ovulate by the injection of 
hormones.  The harvested egg is then fertilized by in vitro fertilization (IVF).  However, before 
the fusion of the male and female pronuclei takes place, the male pronucleus is microinjected 
with the cloned transgene of interest (Figure-3).  The male pronucleus is used specifically 
because it is larger than the female and can be located easier.  The zygote is then allowed to grow 
in culture until the blastocyst stage, then is implanted into a female uterus who has been dosed 
with hormones to be pseudo-pregnant (Cozzi et al., 2009). 
 
 
There are many benefits to this pronuclear microinjection method, including that its 
overall reliability has been proven with decades of results.  Assuming the gene incorporates 
Figure 3: Microinjection of the Male Pronucleus.  (a) Photograph of a rat zygote prepared by in vitro fertilization 
before cell division.  The zygote is held in place with a suction pipette (left side).  Arrows denote male (MP) and 
female (FP) pronuclei.  The male pronucleus is slightly larger.  (b) Microinjection into the male pronucleus with 
micropipette (right side).  (c) Enlarged male pronucleus after microinjection.  400X magnification. (Cozzi et al., 
2009). 
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correctly into the zygote, all cells of the new animal will contain the transgene, including the 
gametes so the transgene will also be passed to the progeny.  However, in this process, the 
transgene does not incorporate in a known location in the genome, and may do so in a location 
that affects the functionality of the cells.  This may result in the embryo not surviving.  In 
general, this procedure must be done many times to get only a few transgenic animals.  This 
procedure has been replaced in many cases by somatic nuclear cell transfer (SCNT), in which a 
skin fibroblast cell nucleus is microinjected instead of an IVF male pronucleus, however the 
technique is still essential in cases where somatic or stem cells have been hard to culture (Verma 
et al., 2007). 
 
Approach 2: Embryonic Stem Cell Manipulation 
The second approach in making a transgenic animal is to manipulate embryonic stem 
(ES) cells instead of the pronucleus.  The beginning part of the procedure is the same, as an 
embryo is formed by IVF, but this time it is immediately grown about 5 days to the blastocyst 
stage. The ES cells are found on the inner cell mass of the blastocyst, and some are removed 
using a needle similar to the one used in the pronuclear microinjection.  Once harvested, the ES 
cells are then cultured in vitro in a medium that inhibits differentiation while preserving their 
pluripotent nature.  The ES cells can then be manipulated to take up the target transgene DNA 
using one of the techniques discussed previously (microinjection into the nucleus, viruses, 
chemicals, or electroporation).  The ES cells are then screened to make sure they are expressing 
the gene of interest (discussed below) prior to being further used.  The transgenic ES cells are 
then returned to the blastocyst which is inserted into a pseudo-pregnant female. 
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The biggest benefit to using this technique is that many more methods can be used to 
insert the target gene.  Some of these methods, especially homologous recombination,  can insert 
DNA into a known location in the genome, which is beneficial in many circumstances.  
However, since only some of the blastocyst‟s ES cells were manipulated to take up rDNA, the 
resulting animal is chimeric, with some of the cells being transgenic and other cells being wild 
type.  But so long as the gametes are transgenic, the chimeric animals can be bred to create pure 
transgenic offspring.  
 
Issues with Microinjection 
 These techniques, when used correctly, can be very effective at producing a transgenic 
animal.  However, the location in which the gene of interest inserts into the host animal is not 
controlled when using microinjection.  This can result in unwanted pathologies and other 
unintended results, and it is best to avoid this if at all possible.  Most higher-order organisms 
have large genomes which are divided into multiple chromosomes and generally are diploid, 
which means they have two sets of the chromosomes.  These chromosomes undergo a process 
called homologous recombination during meiosis which allows them to transfer DNA between 
the chromosomes.  This allows for a solution in which the transgene is targeted to a specific 
location.  By flanking the gene of interest with DNA from the mouse chromosome itself, the 
natural process of homologous recombination will take place, replacing the DNA of the host 
chromosome with that of the gene of interest (Bronson and Smithies, 1994). 
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Somatic Nuclear Cell Transfer (SNCT) 
 Most transgenic animal lines have been created using one of the first two techniques 
discussed above, however a third powerful method has recently been created that allows the 
genetic manipulation of an adult cell‟s nucleus.  Somatic refers to the cells of the body, not the 
gametes, this technique uses nuclei from body cells, and transfers them along with the transgene 
into an egg in which the nucleus has been removed.  Electricity is then used to induce the egg to 
divide, and it is then implanted in the same manner as the other two techniques.  This results in a 
clone with the same DNA as the original cell from which the nucleus was taken.  This technique 
is highly beneficial because body cells can be cultured, and only nuclei that have taken up the 
transgene will be inserted into eggs.  This results in fewer embryos being used, and fewer 
animals being born with unintended defects (Fulka et al., 1998). 
 
TRANSGENIC ANIMAL SCREENING 
Both of these transgenic processes have very low efficiencies, meaning that they must be 
done many times to obtain the desired result.  Techniques for screening these animals have been 
created to test whether the transgene has integrated.  This can be done in a number of ways, and 
following the central dogma, the presence of the transgenic sequences in any or all of DNA, 
RNA, or protein can be used for screening.  These include the use of Western Blots, Southern 
Blots, and polymerase chain reaction assays. 
 
DNA – Southern Blots 
 The first method, the Southern Blot, has many applications for testing DNA.  The 
technique was invented by Edward Southern as a means for detecting specific DNA fragments in 
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a mixture of fragments (Southern, 1975).  It can be used to test how the transgene has integrated 
into the DNA and calculating how many copies have integrated.  Normally a transgene 
integration of between 5 and 10 copies per genome is preferred.  In order to perform a southern 
blot, first DNA is isolated from a very small piece of tail tissue.  Then restriction endonucleases 
are used cut the DNA into smaller fragments, and the pieces are electrophoresed on an agarose 
gel with electric current applied, to separate the DNA fragments by size.  The DNA is then 
transferred to a membrane, and a labeled DNA probe (complementary to the transgene), is 
hybridized to the membrane to visualize any DNA fragments containing the transgene.   
 
RNA – RT-PCR 
 A variant on the DNA amplification method of polymerase chain reaction (PCR) can be 
used to amplify a signal from RNA.  First, RNA is isolated from a tissue of interest.  Then 
reverse transcriptase (RT) is used to synthesize complementary DNA (cDNA) from the RNA.  
Then PCR primers specific to the transgene are used to amplify a signal from the RNA.  If a 
signal is observed, the transgene has been expressed into RNA in that tissue.  The biggest benefit 
of this test is that it is very easy to do with a thermocycler machine doing most of the work.  Also 
smaller samples can be analyzed than with Southern blots, because the signal is amplified during 
the procedure. 
 
 
 
Figure-4:  Example RT-PCR Screening of Transgenic Alzheimer’s Mice.  Lane 
M shows marker bands in basepairs.  Sample in lane-1 shows a positive transgenic 
mouse with an RT-PCR signal at 377 bp (yellow circle) representing the APP 
transgene.  Lane-2 shows a wild-type negative.  (Adams, Personal 
Communication) 
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Protein – Western Blots 
The Southern Blot shows that the transgenic DNA has integrated into the animal‟s 
genome, however it does not determine whether the transgenic protein is being produced.  Since 
this was the intention of inserting the transgene in the first place, it is important to check for the 
presence of the protein.  The Western blot test itself is very similar to the Southern Blot, except 
protein is isolated from the tissue being tested.  The protein is electrophoresed, then blotted to 
membrane, and the membrane is incubated with an antibody against the transgenic protein.  If 
the antibody binds to the membrane in the correct location, the protein of interest is being made 
in that tissue.  However, Western blots are time intensive, and antibodies do not exist to all 
proteins being studied.  Often, creative techniques are used to get around these issues, such as 
tagging the transgenic protein with a series of amino acids for which an antibody already exists, 
however Westerns can be one of the hardest and most expensive of the three tests discussed. 
In the next chapter we discuss applications of these transgenic techniques to create and 
screen transgenic animals, focusing on their benefits to society as a prelude to discussing their 
ethics.  Transgenic applications are nearly endless; however the ethical and legal dilemmas are 
great, and will also be discussed in upcoming chapters. 
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CHAPTER-2: TRANSGENIC APPLICATIONS 
Laura Fineman 
 
 Now that we have described in the previous chapter what transgenic animals are and how 
they are created, we now turn our attention to which ones have been created. The purpose of this 
chapter is to describe the main categories of transgenic animals and to provide examples within 
each category. Special attention will be paid to their benefits to society as this will be important 
in our subsequent chapter on transgenic ethics. 
 
DISEASE MODELS 
 Transgenic disease models are animals that have been genetically modified to mimic 
human diseases for observation and the possible development of drugs or cures. This category of 
animals is especially important when the disease being modeled has no existing cure. Moreover, 
since most types of disease research requires testing on animals before continuing to human 
clinical trials, if no animal model exists for a particular disease it is beneficial to society to create 
one.  Examples of some disease models are the AIDS mouse, Alzheimer's mouse, Oncomouse, 
and Parkinson‟s fly. 
 
AIDS Mouse 
 Acquired immune deficiency syndrome (AIDS) is caused by the human immuno-
deficiency virus (HIV).  HIV infects humans, but does not infect animals, so a disease model 
would facilitate research on HIV treatments. Simian immunodeficiency virus (SIV) infects 
monkeys, and has taught us about this class of virus, but SIV is not HIV. Before the AIDS 
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mouse, little was known about the events that occur directly after systemic HIV infection due to 
the lack of a suitable small animal model.  
 The first AIDS Mouse was a SCID-hu mouse containing human fetal thymus or lymph 
node implants inoculated with HIV (Namikawa et al., 1988). The SCID mouse lacks an immune 
system, so the human lymph node and thymus implants are not rejected. The implants are used to 
allow HIV infection of a human tissue inside the mouse. Incisions were made to expose the 
implanted human tissue, and HIV doses were injected directly into the incisions. The model 
showed that HIV drains to lymph organs during infection, and the developing thymus is a target 
in perinatal infants. The lymph organs were found to have infectable immune cells, such as CD4 
T-cells and monocytic cells. When the thymus was examined, it was found that over 70 percent 
of the infected cells were in the medulla (organ center) as opposed to the cortex. These 
observations are congruent with what occurs in humans, making this a successful model 
(Namikawa et al., 1988). 
 Since the original AIDS Mouse was created, other types of mouse and rat models have 
been created, including inserting co-receptors for HIV entrance, and inserting key host proteins 
required for HIV replication. The rats turned out to be equally good disease models in portraying 
the disease. Their increased size allows for bigger blood samples and greater organ mass for 
analysis, and some of their host proteins facilitate HIV replication unlike their mouse counterpart 
(Reid et al., 2001). 
 
Alzheimer’s Mouse 
 Alzheimer‟s Disease (AD) is a progressive brain disease that is the 7th leading cause of 
death in the United States (Alzheimer‟s Association, 2004). People with this disease have brains 
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containing numerous amyloid plaques surrounded by dystrophic neurites. Amyloid plaques are 
composed of amyloid β-peptide (Aβ) which is a 40-42 amino acid fragment of the β-amyloid 
precursor protein (APP). Aβ is highly neurotoxic and destroys nerve cells. The Alzheimer‟s 
Mouse, created by WPI professor Dave Adams and his colleagues at the former Transgenic 
Sciences Inc., was the first model to express high levels of human mutant APP which mimics a 
family in Indiana with early onset AD (Games et al., 1995). This mouse model produces high 
levels of toxic Aβ in the same areas of the brain that AD patients produce it. It shows extensive 
Alzheimer type neuropathy after approximately 6-8 months. The mouse was generated by 
inserting the gene for mutated (Indiana type) human APP with a platelet-derived growth factor 
promoter to drive its expression in the correct areas of the brain. A transgene splicing that 
permitted expression of all 3 isoforms of human APP contributed to the high levels found and its 
successful AD-like pathology. This model also provides strong evidence for the importance of 
APP (and Aβ) expression in the neuropathy of AD (Games et al., 1995). 
 A few years after the original Alzheimer‟s Mouse was created, Elan Pharmaceuticals 
used it to create the world‟s first vaccine for the disease (Schenk et al., 1999). The immunogen 
was a synthetic human Aβ42 (a major component of β-amyloid plaques). Almost all the mice 
immunized with Aβ42 developed and maintained significant amounts of serum antibody 
concentrations against the toxin, and the clearance of the toxin almost completely prevented 
senile plaque deposition. Thus, the systemic injection of Aβ42 and the formation of antibodies 
against it appears to reduce the levels of the toxin; Aβ42 antibodies either prevent Aβ deposition 
or enhance its clearance from the brain (Schenk et al., 1999). 
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Oncomouse 
 Oncomouse was one of the first transgenic animals ever produced, and was the first 
transgenic animal patented. This disease model contains a human oncogene and develops human 
type tumors, enabling it to serve as a model for understanding cancer formation and for screening 
anti-tumor drugs. It was developed for cancer research and actually consisted of 13 different 
strains of transgenic animals, collectively referred to as Oncomouse. Oncomouse contains a 
fusion transgene (MTV/myc) containing a human proto-oncogene c-myc with most of the 
upstream promoter region replaced with a hormonally inducible mouse mammary tumor virus 
promoter (MTV). The expression levels of the transgene varied among the female progeny, but 
all of the females that inherited the transgene developed mammary adenocarcinomas during their 
pregnancies. It was deduced that the regulated myc gene acts as a heritable, predisposing factor 
favoring the accelerated development of tissue-specific adenocarcinomas (Stewart et al., 1984). 
The patent was awarded four years after being filed, on April 12, 1988 (Leder and Stewart, 
1984). 
 
Parkinson’s Fly 
 In 2000, a model for Parkinson‟s Disease (PD) was made; not with a mouse, but with the 
fruit fly (Drosophila) (Feany et al., 2000). PD is a neurodegenerative syndrome characterized by 
loss of dopaminergic neurons in the substantia nigra. Dopamine is a neurotransmitter that helps 
regulate neuromuscular transmission, so its loss leads to abnormal muscular control. The cause 
of PD is unknown, but in some genetic cases it is caused by mutations in the α-synuclein gene; 
this mutation triggers α-synuclein to accumulate in Lewy bodies and Lewy neurites causing their 
degeneration. In this disease model, mutant (A30P) α-synuclein and mutant (A53T) α-synuclein 
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genes were inserted into transgenic flies.  The flies‟ nervous systems formed appropriately, but 
after 30 days the dorsomedial dopaminergic neurons were absent. The model accurately 
represents the three key features of the pathology: adult onset, involvement restricted to the 
nervous system, and anatomical specificity. Some of the flies also experienced retinal 
degeneration in addition to neurodegeneration, proving that α-synuclein-related degenerative 
changes show relative rather than absolute specificity for dopaminergic neurons (Feany et al., 
2000). 
 
TRANSPHARMERS 
 Before the technology of transpharming was developed, biologically important proteins 
such as human growth hormone or insulin were harvested from human cadavers or from 
slaughtered pigs, respectively. However, research is currently being performed on the production 
of human pharmaceuticals in genetically modified farm animals (Biotech Info Series, 1995). This 
transpharming technology was first implemented in mice, but is now moving to larger animals 
such as sheep, goats, and cows due to their larger milk production. 
 
Transpharmer Mice 
 A group in Framingham, MA created a mouse that was genetically modified to produce 
human tissue plasminogen activator (t-PA) in it‟s milk. t-PA is a protein that functions as a clot 
dissolver, so it can be used for treating heart attacks and strokes. The t-PA gene was fused to the 
murine whey acid protein (WAP) gene. WAP is the most abundant protein in mouse milk, so by 
using its promoter the t-PA gets expressed only in the milk. The level of WAP RNA in the 
 22 
mammary gland increases about 340-fold in lactating females. This model proved the feasibility 
of producing human proteins in the milk of animals for commercial use (Gordon et al., 1987). 
 
Transpharmer Sheep 
  Four sheep were successfully genetically engineered in Edinburgh, Scotland by 
pronuclear injection of a fusion transgene derived from a sheep milk protein β-lactoglobulin 
(BLG) promoter (to drive expression in the milk) and a human anti-hemophilic factor IX (a drug 
used to treat specific clotting disorders). Not only did the two ewes secrete human factor IX in 
their milk, but both gave birth to lambs with the same trait (Clark et al., 1989). 
 
Transpharmer Goats 
 Recently, GTC Biotherapeutics Corp. received FDA approval to market ATryn®, which 
is the world‟s first FDA-approved transpharmed drug. The drug is a recombinant form of human 
antithrombin (ATIII) for the prevention of peri-operative and peri-partum thromboembolic 
events in hereditary antithrombin deficient (HD) patients. The transgenesis was accomplished by 
using cell fusion of a transgenic cell to an enucleated egg. The fusion gene consisted of a milk 
protein promoter and the ATIII gene. The company is also developing other recombinant forms 
of additional human plasma proteins, such as albumin and alpha-1 antitrypsin (ATryn®, 2008). 
 
Transpharmer Cows 
 Perhaps the most famous transpharmer is a Dutch bull named Herman, born in 1991. 
Herman was the world‟s first transgenic cow. The gene for human lactoferrin (hLF) (an 
antimicrobial agent present in normal mother‟s milk but not in cow‟s milk or in synthetic 
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formula) was microinjected into immature oocytes, then the embryo was implanted by non-
surgical transfer. Twenty-one pregnancies and 19 calves later, two calves tested positively for the 
lactoferrin gene. The female was a mosaic; the gene was found in the placenta, but not the blood 
or ear tissue. But the male was transgenic in all three tissues, and was later named Herman 
(Krimpenfort et al., 1991). He later went on to father at least 8 calves in 1994, all containing the 
lactoferrin gene (Biotech Notes, 1994). 
 
XENOTRANSPLANTERS 
 Ever since the introduction of immuno-suppressor drugs, transplantation has become the 
preferred treatment for advanced organ failure. However, a very limited supply of human organs 
is leading to an alternate approach of using animal organs. This process is called 
xenotransplantation (transplantation between species). The primary animal of choice is the pig, 
due to its relatively close physiology with humans, ethical considerations, and its relatively 
compatible organ size. The major barrier of using pigs is the presence of terminal [alpha]-1,3-
galactosyl (Gal) epitopes on the surface of pig cells. Because humans have lost the 
corresponding galactosyltransferase activity during evolution, we lack Gal epitopes on the 
surface of our cells. This causes its presence in pig cells to be viewed as foreign by humans, 
leading to hyperacute rejection of the pig organ. Several solutions have been suggested, 
including Gal antibody removal or competitive inhibition, although these methods are not 100 
percent effective. An alternative way has been to genetically knockout the transferase gene that 
encodes the enzyme that adds on this “foreign” sugar using embryonic stem cell technology (Lai 
et al., 2002). The first knockout pigs were shown to have a successful knockout of the gene, and 
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they are all heterozygous for the knockout. The next step is to create homozygous knockout pigs 
and to test their organs in transplantations (Lai et al., 2002). 
 Pig heart valves are currently used for heart valve transplantations, so there is already a 
basis for transplanting animal tissues into humans, but there are several concerns about 
transplanting entire animal organs. Most of the concern is of pig viruses crossing the species 
barrier, whether the viruses represent new infectious agents or asymptomatic viruses in pigs that 
become active in humans (Catez, 2005). However, the organ waiting lists remain miles long, and 
people on the lists die every day awaiting transplants, so there is a desperate need for organs, and 
xenotransplantation just might be a good enough answer. 
 
TRANSGENIC FOOD SOURCES 
 Transgenic animals have also been created to potentially provide new sources of food. In 
the cases of superpig and superfish, growth hormones were inserted to create animals that mature 
faster on less food to commercialize them as food sources. 
 
Superpig 
 This animal contains an ovine metallothionein-1α (oMT1α) promoter (to allow strong 
zinc-induced expression in a variety of tissues) fused to ovine growth hormone (oGH) (to 
facilitate rapid growth of the animal) (Pursel et al., 1997). The fusion gene was microinjected 
into 400 pig zygotes; from this, 15 piglets were born. Of the 12 assayed, 5 contained high levels 
of oGH, 1 contained low levels, and 6 had none. A dietary supplement of zinc increased the 
plasma oGH of the piglet with low levels by 20-fold. Although the incorporation of the oGH 
transgene was successful, there is still a need of improved transgenic methodology in pigs; 
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microinjection of growth hormone into mice and sheep is far more successful in terms of percent 
born being transgenic (Pursel et al., 1997). 
 Although the goals (increased rate of gain, increased feed efficiency, and decreased 
carcass fat) were achieved, significant suffering of the animals occurred after about 6 months of 
age. Some problems observed were that of the kidney and liver, lethargy, uncoordinated gait, 
degenerative joint disease, gastric ulcers, various heart diseases, and pneumonia; this lead to the 
euthanization of the animals. Because of these severe health effects, the scientific community 
imposed a moratorium on performing growth hormone experiments in mammals (Rollin, 1996). 
 
Superfish 
 Although growth hormone experiments in pigs were a disaster, similar experiments 
performed in fish for aquafarming purposes proved far more successful. Several companies, 
including Aquabounty Technologies, are near to getting FDA approval to aquafarm transgenic 
salmon and trout (Aquabounty Technologies, 2009). Aquabounty specifically has created an 
AquAdvantage® fish, an advanced-hybrid salmon, trout, and tilapia hybrid designed to grow 
faster than traditional fish. This fish is designed to reach marketable size twice as fast as 
traditional fish, a compelling economic benefit to farmers. The fish is also reproductively sterile, 
eliminating the threat of interbreeding amongst themselves or with native populations if they are 
accidently released (Aquabounty Technologies, 2009). 
 Although being sterile has its benefits to preserving native fish populations, there are still 
other concerns about what might happen if the containment pen breaks, including concerns about 
the released fish competing with native fish for food, or being able to survive better with climate 
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changes or less food. The released fish could also spread to other areas to become an invasive 
species (Stokstad, 2002). 
 
SCIENTIFIC MODELS 
 These scientific models have been created to teach us something about the function of a 
newly discovered protein by overexpressing the gene or by knocking it out. 
 
ANDi the Monkey 
 In 2001, a green fluorescent protein (GFP) gene contained in a retroviral vector was 
injected into the perivitelline space of mature rhesus oocytes. The GFP transgene was used as a 
marker to prove that transgenic primates can be created, although its physiology would not be 
altered.  The transgenic oocytes were then fertilized in vitro, grown to the blastocyst stage, then 
implanted into the uterus of a pseudopregnant female. Three males were born, and one of them 
was successfully transgenic; his name was ANDi (inserted DNA spelled backwards). There was 
GFP direct fluorescence in his toenails, hair, and placenta; however, ANDi does not glow (Chan 
et al., 2001). At the moment, it is unclear if his sperm contains the transgene as well; if so, he 
will be able to pass it on to his offspring and more research can be done. The development of 
ANDi also raises many concerns about creating transgenic primates, (Begley, 2001) which will 
be discussed in Chapter-3. 
 
Smart Mouse 
 According to Hebb‟s Rule in 1949, learning and memory are based on modifications of 
synaptic strength among neurons that are simultaneously active. This rule implies that better 
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synaptic coincidence leads to better learning and memory. The NR2B subunit of the NMDA (N-
methyl-D-aspartate) glutamate receptor (the synaptic coincidence detector) predominates when 
the brain is forming, and is thought to act as a graded switch for memory formation. This 
hypothesis is what a group at Princeton set out to test, and it proved to be right (Tang et al., 
1999). Mice over-expressing the NR2B subunit of the glutamate receptor were seen to have 
better long term memory than their non transgenic littermates. One hour after they were 
introduced to objects and taught new ones, both sets of mice did equally well; however 3 days 
later only the smart mice remembered their training. After one week though, neither remembered 
(Tang et al., 1999). 
 
Supermouse 
 Supermouse was created using the same transgenic growth hormone technology used 
later to create Superpig and Superfish.  Supermouse was the world‟s first transgenic animal in 
which the transgene actually produced a visible phenotypic change. Slightly earlier models were 
transgenic, but did not express the transgene. The promoter used was mouse metallothionein-I (a 
very effective strong promoter) which was fused to the structural gene of a rat growth hormone. 
The transgene was then microinjected into the pronuclei of newly fertilized mouse eggs. The 
fertilized eggs were grown to the blastocyst stage, then implanted into the uteri of 
pseudopregnant mothers. Of the 21 mice born, seven carried the transgene and six were much 
larger than their littermates. Like Superpig, the mouse diet contained zinc supplements to help 
drive expression of the growth hormone to enhance their growth. Although when this model was 
first created in 1982, it had the potential for being a model for gigantism and for correcting 
genetic diseases affecting height (Palimiter et al., 1982), the growth hormone technology was 
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subsequently dropped after the 1997 Superpig fiasco. However, the growth hormone technology 
originated with this animal is currently being used commercially for transgenic fish, as 
mentioned previously for Superfish. 
 
Youth Mouse 
 In 1999, mice were created carrying the entire coding gene of murine urokinase-type 
plasminogen activator (uPA) linked downstream from the promoter of lens-specific αA-crystallin 
gene (Miskina et al., 1999). These α-MUPA mice live about 20 percent longer than normal mice 
by eating less. These mice have a reduced body temperature, higher plasma corticosterone, 
maintain a young look, and for the most part resemble healthy dietary restricted mice. Although 
overall they seem healthy, they do show a high frequency muscle tremor in all legs when placed 
in a non-stable position, such as sustained by their tail. However, this is only seen in 
homozygous α-MUPA mice, not heterozygous, and their other motor behaviors appear normal 
(Miskina et al., 1999). 
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CHAPTER-3:  TRANSGENIC ETHICS 
John Raymond Martin 
 
At all times in human history, great progress has coincided with great atrocities.  As 
transgenics makes great strides, it is important that we do not commit the crimes of our past and 
that we evaluate the consequences of this emerging technology, one that is hardly comparable to 
any in our collective histories.  The benefits to society of doing transgenic animal experiments, 
discussed in the previous chapter, could be substantial, however many see this type of 
technology as having stepped into a realm man was never meant to exist in.  For many people, 
altering organisms at the core level of DNA is akin to playing god.  They see using animals for 
any kind of research as cruel and immoral.  Others feel that animals are here to service us, and 
transgenic experiments are just one addition to the laundry list of current uses.  Some people 
only see using this technology on humans as wrong, while accepting it on animals.  Some 
transgenic animals live comfortably for their entire lifespan, while other suffer and die early.  
This large disparity in beliefs, and the significant disparity in the transgenic animals themselves, 
means that an answer cannot be derived for the entire subject.  For that reason this chapter goes 
beyond the transgenic applications previously discussed to focus on ethical perspective to help 
elucidate whether the benefit to society is truly worth it.  This chapter will initially be written in 
a position-neutral manner, because these disparities make transgenic ethics an especially difficult 
area.  At the end of each application a litmus test will be used by the author to put that 
application into perspective.  This test will look at three areas: (1) harm to the animal, (2) benefit 
to society, and (3) whether it crosses the line of mainstream morality.  At the end of the chapter, 
the author‟s main conclusions and opinions will be presented. 
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ANIMAL ETHICS 
 Several systems exist for evaluating the ethics of a situation, the two classical systems are 
utilitarianism and deontology.  Utilitarianism has just one criterion: utility.  This results in a 
balancing act in which the greatest difference between good and bad is encouraged.  Deontology 
does not look at just the consequences of an action but also moral principles.  However, this can 
also result in a complex balancing act, especially as the principle of not harming animals is 
weighed against saving cancer patients.  A third system, that of the “network model”, constitutes 
six principles: beneficence (promoting the well being of the animal), non-malfeasance (not 
harming the animal), justice (equal treatment of similar animals, and fair distribution of good and 
evil between the human and animal), integrity (physical and genetic), irreversibility (the idea that 
risk should be minimized because of the irreversible nature of biotechnology), and verifiability 
(that there should be a public debate on the regulations which govern the technology) (Boer et 
al., 1995).  In general, the integrity principle will be taken to mean physical integrity, as all of the 
animals discussed in this project lack genetic integrity by being transgenic.  These three systems 
will be balanced when using our litmus test for each application.  There exists the possibility that 
one system may disapprove of a particular animal while still be considered acceptable by the 
author because the balancing leans more heavily towards the use of the animal. 
 
TRANSPHARMER ETHICS 
 Transpharming is the practice of using animals as bioreactors capable of producing some 
kind of pharmaceutical product.  The standard way of doing this is to engineer the animal to 
express the foreign protein in the milk because it results in high yields while doing little to no 
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harm on the animal itself.  Another benefit of production in the milk is that milking an animal is 
a long-standing industry with significant technology to extract the product in a way that does no 
harm to the animal.  Since the animals live full lives without any behavioral sign of the 
transgenesis, it is hard to have a significant argument against this type of transgenic application.  
Another key benefit to transpharming is that the animals are portable; they can be brought to 
other areas of the globe needing drugs such as antibiotics or HIV medication, including areas 
without electricity.  As far as our litmus test: there is no detectable animal suffering as long as 
there are no defects in the transgenesis process, and the benefit to society producing life saving 
medicines is great, without putting mainstream morality at risk. 
 
XENOTRANSPLANTATION ETHICS 
 It comes as a shock to most people to think about humans having their blood cleaned by a 
pig; however the next step in this field is using animals to grow human organs and then 
transplant them back into humans (Butler, 2002). The lack of human organs to serve critically ill 
patients awaiting human organ transplants is one of the primary reasons this technology is being 
pursued.  Even when there are organs available, they are not always histocompatible with the 
patient.  This means that there are receptors on the organ that the patient‟s immune system 
recognizes as foreign and mounts a response against it.  Even patients that are histocompatible 
must take immunosuppressive drugs that can stop the immune system from reacting to other real 
infections, and these drugs have powerful side effects.  Since organ transplantation is major 
surgery and involves the insertion of a foreign organ that potentially came from a donor that is 
infected by a virus, even at small amounts of immunosuppression, the presence of a virus can be 
very dangerous.  Xenotransplanters however are transgenic animals that have had the receptors 
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that cause this immune reaction removed.  They have also been grown in a sterile environment, 
which means the risk of infection after surgery is greatly reduced.  There is the concern that 
people with animal organs could incubate any virus present, and cause animal diseases to jump 
to humans.  Since the animal organ would be inside the human the virus would have a chance to 
evolve in an environment (a mixture of human and animal cells) beneficial to crossing species.  
This risk can be reduced by testing for known viruses, and maintaining sterile conditions while 
the animal is raised.  However, even normal individuals always have the possibility of coming 
into contact with a pig virus and creating a new human virus that could spread to the population.  
Mainstream ethics which says it is acceptable to raise a pig to be eaten (which involves animal 
death), makes it very hard for a mainstream rejection of this kind of transgenic animal on the 
basis of animal cruelty.   
However, the future of this technology includes many more ethically ambiguous areas 
such as their use in cosmetic surgery.  Growing a new face on a pig then transplanting it onto a 
human is ethically ambiguous; however it is a future whose ethics must be considered today.  
The idea of using a pig organ as a last resort when a human organ is not available is not nearly as 
ambiguous, as it would be a life or death situation that most would see as a necessity if available.  
This difference is evident in the justice principle, in the case of the heart transplant a pig dies to 
save a deathly ill human, while in the cosmetic case the pig dies so that the human could look 
better.  Our litmus test shows that there is little suffering to the animal (as much as with any 
other farm animal) and the benefits to society are great, however some say our morality is at risk 
if humans take xenotransplanting too far. 
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TRANSGENIC DISEASE MODEL ETHICS 
 The area of disease models is where the real ethical concerns, for most, start to appear.  
Not all of the animals discussed in Chapter 2 live full or pain free lives.  All of the animals in 
Chapter 2 have the potential to be of great benefit to society, although there was little balancing 
needed for the first two applications, the benefit must be weighed against the harm to the 
animals. 
 
Alzheimer’s Mouse 
 First produced by this project‟s adviser, Dave Adams, the Alzheimer‟s mouse does not 
suffer in any detectable way.  Alzheimer‟s research is key to curing a disease that affects 
millions, and has no effective treatment.  These mice are used as part of research which includes 
collecting samples, testing new drugs, and eventually sacrificing the animal so that its tissues can 
be tested.  The litmus test here shows that there is little mouse suffering, and while during 
research the lifespan may be shortened significantly, there exists a moral imperative to find a 
treatment for this devastating disease. 
 
Parkinson Fly 
 This model system benefits from being in a lower order animal, however this brings out 
different objections.  While there are no significant animal welfare concerns to this type of insect 
research, there are objections to making such a portable animal containing transgenes for fear 
that it might escape.  While larger animals are easy to track, and only produce small litters, flies 
are small and produce very large amounts of offspring.  An accident in 1957 resulted in African 
“killer bees” being released into North America which allowed cross breading with native bee 
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species.  Such an accident according to the irreversibility principle must be done in a laboratory 
that does not allow the chance for the flies to escape or breed with other non-transgenic species. 
The litmus test here shows no concerns for the animal itself, but concerns that society could be 
affected in unknown ways if the fly were to escape. 
 
AIDs Mouse 
 Since HIV cannot naturally infect mice, a transgenic solution was needed to create an 
animal model for testing potential treatments.  These mice have been made so that their engrafted 
human tissues are not rejected by using the SCID knockout to compromise their immune system.  
This leaves the mice unable to fight off infections, and they essentially suffer from the “bubble-
boy” syndrome and must be kept in a sterile environment to stop them from dying.  This 
transgenesis causes suffering on the part of the mouse that is not insignificant.  The seriousness 
of the diseases‟ prevalence however makes it a moral imperative that it be researched and 
treated.  This is a case where the litmus test shows animal suffering, however because of the 
massive scale of AIDS, the moral imperative, and the overall benefit to society such research 
will bring, mainstream ethics says that this is important to do. 
 
Oncomouse 
 Cancer kills millions of patients per year, and current treatments in many areas are not 
adequate.  Although HIV crossed species from chimpanzees in this century, cancer has been with 
the human race since its inception.  Most cancer develops later in life, and kills at a fairly slow 
rate, although some cancers affect children in early life and cause many early deaths.  Oncomice 
show most of the symptoms of a person who has cancer, and are used to learn about what 
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initiates cancer, and for screening potential drugs.  But tumors grow which cause pain, and the 
mice can die early.  This model for some people gets murky.  With respect to the litmus test, 
there is animal suffering, although strong regulative oversight from animal care committees 
usually requires the use of pain killers and sacrifice of the mice prior to advanced tumor 
formation.  However cancer, one of the top killers in the world, pushes many people (including 
the author) to find it a worthwhile endeavor to use these mice to do research with continued 
strong oversight from institutional animal care and use committees (IACUC). 
 
TRANSGENIC FOOD SOURCE ETHICS 
 Transgenic farm animals seek to increase the speed of the breeding programs that have 
been going on for many centuries to bring about animals that provide more food faster.  These 
animals produce hormones at an accelerated rate that causes them to mature at a significantly 
faster rate.  Because of the increased growth rate, these animals require less food per pound of 
meat produced than their non transgenic littermates.  However, there is general public distain at 
the idea of genetically modified food, and people worry that the hormones increased in the 
animals will be ingested.  Parents are especially cautious of giving anything that has been 
genetically modified or has been given growth hormones to their children (Environmental News 
Service, 2000). 
 Ideally animals in this realm should follow the “principle of conservation of welfare” 
which was proposed by Bernard Rollin, and states that “genetically engineered animals should be 
no worse off than the parent stock would be if they were not so engineered, and ideally should be 
better off” (Rollin, 1996). Efforts to increase efficiency have resulted in significant suffering that 
cannot be balanced with a societal concern.  It is true that there are people without food in parts 
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of the world; however this has just as much to do with economic, transportation, and political 
issues than the inability to produce enough food.  As of 2009, the FDA has finally put a 
regulatory mechanism in place for the approval of transgenic food products and drugs (FDA, 
2009).  The author believes that transgenic animals that will be eaten must meet very high 
standards, and that the FDA should evaluate the use of these animals carefully for the safety to 
the human population as well as the welfare of the animal population. 
 
SCIENTIFIC MODEL ETHICS 
 By over-expressing a specific gene, or by knocking it out, scientists are able to discover 
its purpose.  This type of research is often in the category of expanding scientific knowledge, and 
is often hard to measure ethically because there is no pressing societal issue pushing for the 
research to be done.  However, often times this type of research is the most “pure” because it is 
the least influenced by businesses trying to make money, it is done in the pursuit of knowledge 
for knowledge sake. 
 
ANDi the Monkey 
 ANDi was created as a proof of concept that transgenic monkeys could be made.  Such 
animals may eventually serve as human disease models.  ANDi was created with an “inert” 
transgene, green fluorescent protein, which only served as a marker for transgenesis, but created 
no symptoms.  ANDi is different from the other disease model animals because his genome is so 
close to that of a human which makes this research directly applicable to transgenesis in humans, 
although the researchers say that they would never support doing transgenesis in humans.  They 
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especially want to distant this type of research from the public image of a society in which 
everyone had the option of swapping in or out genes for their children (Begley, 2001). 
 The litmus test on ANDi is hard because while ANDi himself is a scientific model, the 
research was done so that more monkeys could eventually become disease models.  ANDi 
himself does not solve any societal issues, but the technological development will allow for 
future disease research, which in turn could prove useful for disease such as HIV which is very 
hard to study in other animal models.  Monkey research is often the tipping point for people in 
their ethical struggle.  People have always been turned off by research in primates because of 
their close relation genetically and morphologically.  It is this resemblance however that can 
make monkey research that much more fruitful, and when done in a controlled manner it is 
possible that the ethical balance should allow for it. 
 
Other Scientific Models 
 In general, based on the literature, most of the transgenes chosen for use in scientific 
models are advantageous to the organism.  For example, “youth mouse” lives longer than normal 
mice, “supermouse” is bigger than normal mice, and “smartmouse” learns faster than wild type 
mice.  However, there are often unintentional consequences of the experiment.  While “youth 
mouse” lives longer, researcher noticed that its legs quiver more than usual (Miskina et al., 
1999).  While this may not seriously affect the mouse, it brings about important questions about 
using animal models.  Unlike humans, animals are unable to communicate the „little pains‟ that 
transgenesis brings to them.  Instead, scientists look for signs such as eating, reproductive 
behavior, noises, shaking, how playful they are, and other measures to determine the animal‟s 
quality of life and whether they are suffering. 
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CHAPTER-3 CONCLUSIONS 
 While considering the ethics of a developing subject, it is import to do so in the light of 
Gresham‟s law which says that “bad money will drive good money out of circulation”.  This 
implies that in any new situation when no consensus exists, the outliers will be what is brought to 
the surface.  While society is being significantly benefited by the advent of transgenic 
techniques, at every step in the path our discussion must evolve.  When in vitro fertilization first 
allowed people to have babies that initially could not because of medical issues, the same ethical 
issues surfaced, the concern that society would change to a race of genetically modified part-
humans; and this remains valid in many minds.  And in some ways it should be, as corporations 
realize that there is great profit in the life sciences, the same companies that today make 
cosmetics and breast implants could tomorrow be offering full body transplants.   
However, it is important that the discussion of transgenesis does not move away from the 
documented good of what is going on.  I like to think of Greshman‟s Law as an equation such 
that increasing the good money (ethics) will out compete the bad money (profit driven negative 
experiments).  It is the author‟s conclusion that most of the transgenic research being done today 
is in the right.  Curing HIV, Alzheimer‟s, and cancer are clear social and moral imperatives.  
These diseases detract from society in immeasurable ways, which should attract many to 
promote transgenic research.  The next chapter of this project will take an in-depth look from a 
legal and regulatory perspective on the use of transgenic animals. 
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CHAPTER-4: TRANSGENIC LAWS 
Laura Fineman 
 
 In the previous chapter, the ethics and controversies of producing transgenic animals 
were discussed. In this chapter, the focus will be on how society regulates the use of this 
interesting technology, especially through animal patenting. Animal patenting is a highly 
controversial topic; how much is society is willing to patent, and where should it stop? 
 
NEW PATENT APPLICATIONS 
 When applying for a new patent, inventors must fall into one of three categories: utility, 
design, or plant patent. Utility patents are granted to those who invent or discover a new and 
useful process, machine, article of manufacture, or composition of matter, or any new and useful 
improvements. Design patents are granted to those who invent a new, original, ornamental 
design for an article of manufacture. Plant patents are granted to anyone who invents or 
discovers and asexually reproduces any distinct and new variety of plant. In addition, any new 
invention or discovery must be novel as well as non-obvious. (United States Patent and 
Trademark Office, 2005) 
 
ANIMAL PATENTS AND FDA APPROVAL 
 In 1980, following the 1970s landmark case of Diamond vs Chakrabarty to allow the 
patenting of microbes (discussed below), the Supreme Court ruled that novel living microbes can 
be patented. However, with respect to animals, after the original 1984 Harvard Oncomouse 
patent received backlash from many animal rights groups (discussed below), the government self 
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imposed a moratorium on animal patents for several years (Andrews, 1993). After the 
moratorium was ended, several transgenic mice received patents, including two more patents for 
a different oncomouse (Leder and Stewart, 1992, 1999), a mouse carrying a non-infections HIV 
genome (Jolicoeur, 1994), a mouse model for Kaposi‟s sarcoma (Lira and Yang, 2000), and a 
mouse expressing amyloid beta to be used as an Alzheimer's model (Stern and Yan, 2000). 
 In addition to the government‟s Patent and Trade Office (PTO) controlling patenting, the 
government‟s Federal Drug Agency (FDA) plays a big part in the control of transgenic products. 
After a decade of fierce debate, the FDA finally decided how genetically engineered animals will 
be evaluated to benefit the public. Such animals will be regulated under the Federal Food, Drug, 
and Cosmetic Act; the recombinant DNA in the animal will be the „drug‟, and its safety and 
environmental impact will be investigated (FDA to Regulate the Use of Transgenic Animals, 
2009). This landmark decision on how to regulate transgenic animals was soon followed by the 
first FDA approval of a biological product produced by genetically engineered animals 
(FDA.gov, 2009). The product is called ATryn®, an anticoagulant used for the prevention of 
blood clots in patients with hereditary antithrombin deficiency. ATryn® is produced in the milk 
of transgenic goats, maintained at a farm in Charlton, Massachusetts (GTC Biotherapeutics, 
2006). Although these new guidelines provide a key step for evaluating transgenic products for 
FDA approval, it is still a new idea, and a potentially disastrous one to both the FDA and 
biotechnology companies. 
 
DIAMOND VS CHAKRABARTY (First US Patenting of a Microbe) 
 In 1972, microbiologist Ananda M. Chakrabarty filed a patent application for a 
genetically engineered bacteria that was able to break down crude oil. This bacterium was 
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derived from the genus Pseudomonas and contained two different plasmids, each with a separate 
pathway for crude oil degradation. This organism was intended to be used as a treatment for oil 
spills; no naturally occurring bacteria is able to do this. The patent included three claims: (1) the 
process for producing the bacteria, (2) for an inoculum comprised of a carrier material floating 
on the water, and (3) the bacteria themselves (Diamond vs Chakrabarty, 1980). 
 After examination, a patent examiner accepted the first two claims, but not the third 
under the reason that living things are not patentable. The case was appealed to the Supreme 
Court, where it was eventually ruled that Chakrabarty‟s microorganism constituted a new 
„manufacture‟ or „composition of matter‟ because the trait is not nature‟s handiwork. The court 
decided that microorganisms can indeed be patentable subject matter under patent law. Diamond 
vs Chakrabarty became a landmark court case, and the bacterium became the first living thing to 
be patented in the United States (Diamond v. Chakrabarty, 1980). 
 
ONCOMOUSE LEGALITIES 
 Although the Oncomouse was not the first life ever patented, it was the first transgenic 
animal patented. The patent was awarded on April 12, 1988 to Harvard and DuPont‟s mouse 
containing a recombinant activated oncogene (Leder and Stewart, 1984). The patent covers all 
mammals, and more specifically the ancestors of the animal that first received the oncogene 
(Leder and Stewart, 1984). Two subsequent oncomouse patents followed the original; for the 
method for providing a cell culture from a transgenic non-human mammal (Leder and Stewart, 
1992), and for testing methods using transgenic mice expressing an oncogene (Leder and 
Stewart, 1999). 
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 For the original patent, there is some argument about what is legally covered. While the 
oncomouse itself is an entirely new entity, the technique for oncogene insertion was not new yet 
is part of the patent. The patent also covers oncogene insertion into any mammalian species, an 
arbitrary boundary that goes far beyond what was actually invented. Awarding a narrower patent 
could open up doors for competition and independent development as well as better ideas 
(Stallman, 2002). However, currently DuPont is becoming more assertive about asking United 
States researchers to obtain licenses to use the Oncomouse (Marshall, 2002), and the company is 
asking institutions to enforce the licensing agreements. Some institutions have adhered to these 
requests, but Massachusetts Institute of Technology and the University of California have not yet 
done so (Marshall, 2002). 
 
ONCOMOUSE IN CANADA 
 Although the Oncomouse patent was approved in the United States, in Europe, and in 
Japan, it was denied in Canada (Check, 2002). On December 5, 2002, the Supreme Court of 
Canada rejected the patent application for Oncomouse. The court agreed with the Canadian 
Council of Churches and the Evangelical Fellowship of Canada who both had arguments against 
the commodification of life (Mitchell and Somerville, 2002). According to Canada‟s Patent Act, 
higher life forms are not deemed patentable because they are not a „manufacture‟ or a 
„composition of matter.‟ However, the claims on the process used to make oncomouse were 
granted a Canadian patent (Check, 2002). 
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Benefits of Patenting Animals 
 Over the last several decades, technology and technological innovation has gradually 
replaced manufacturing and agriculture as the main economical drivers (Blaug et al., 2004). For 
example, the transgenic industry has grown with inventions of things like protein secretion in 
milk, disease models for drug testing, and faster growing food sources. However, such research 
is expensive. Patent protection for transgenic animals could be a good reward for companies 
willing to undertake the risky and expensive research, development, and manufacture. Many 
people believe that biotechnology holds the key for finding cures of diseases, improving food 
quality, making pharmaceuticals more cost-effective, and above all, that the benefits outweigh 
the possible costs (Walter, 1998). So with respect to benefitting society, the protection of 
biotechnology inventions may not necessarily be a bad thing; by protecting new discoveries that 
may provide cures for diseases, you protect the industries making those discoveries. 
 
Potential Detriments to Patenting Animals 
 Although there are many benefits associated with patenting animals, there are also some 
concerns. For example, there are moral and religious concerns, animal rights concerns, and 
environmental concerns.  It is important to note various religious beliefs and their views on how 
to treat animals. Many Jews and Christians follow the Old Testament‟s teachings in that all life, 
including animal life, is sacred.  Hindus also see divinity in all living creatures, that animals are a 
form of re-incarnation, and that cows are sacred.  Therefore, they would be against things such as 
transgenic cows (Curran and Koszarycz, 2004).   
 Several animal rights groups also protest transgenic animals and animal experimentation.  
One of the most visible of these groups is People for the Ethical Treatment of Animals (PETA). 
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PETA is predominately concerned with animals in labs and their rights, and are attempting to 
end all animal testing.  The Animal Welfare Act requires labs to report the number of animals 
used in experiments; however, this does not include mice, rats, and birds which are used in 80 to 
90 percent of all experiments. However, a big factor going against PETA‟s war opposing animal 
testing is the FDA requirement that all drugs need to first be tested on animals (PETA.org, 
2009).  
 With respect to environmental concerns, if a genetically engineered animal is released, or 
escapes into the wild, what is the environmental harm if the animal breeds with native species? 
So strong oversight is needed to mandate such animals are handled only in licensed vivariums.  
And with respect to economics, farm animals altered to grow faster or bigger may result in small 
family farms being unable to compete (Walter, 1998).  
 There are also some concerns with the patenting process itself being too broad; the 
Oncomouse patent is a prime example of this (Stallman, 2002). Although university 
collaborations with research companies are beneficial to both sides in terms of creating new 
inventions, there is an unclear boundary for balancing academic access to information and the 
created strains versus the company‟s rights to patent their technology. This disagreement is 
currently happening with Oncomouse, as DuPont has become very aggressive in enforcing 
licensing and collecting royalties from academics for its role in the invention (Marshall, 2002; 
Blaug et al., 2004). Some argue that an extreme industry position of broad patents could severely 
inhibit disease research in smaller research facilities that may not be able to pay the licensing fee. 
In the end, society would lose out. 
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PROJECT CONCLUSIONS 
 
 
This IQP research allows for conclusions to be made by the authors.  The overall 
conclusion is that animal suffering should be tightly regulated and balanced with reasonable 
societal needs. Certain transgenic animal types have been agreed upon by the authors as 
acceptable (see below); however, the authors disagree on others. Strict regulation by Institutional 
Animal Care and Use Committees (IACUC) and by the FDA should be continued to maintain the 
strong oversight required with this technology. It is also agreed that while transgenic animal 
patenting is beneficial, changes need to be made to the patenting system to allow for the greatest 
innovations. 
Transpharmers are considered by the authors to be the best type of transgenic animal due 
to the great medical benefits to society, with no apparent health problems for the animal. 
Although there is some worry about xenotransplantation, with the right precautions for 
euthenasia, this area can be also very beneficial for saving lives with no unusual harm to the 
animal, except for the harvesting of the organs.  The authors also believe that, as long as strong 
regulation is placed upon the transgenic creation of food sources to eliminate animal suffering, 
this will also be a good use of transgenic technology.  For scientific models, for now the benefits 
appear to far outweigh the detriments, but there is some concern about future research on these 
models, particularly with creating transgenic primates, as primates are very closely related to 
humans.  The last type of transgenic animals, disease models, is where the authors of this IQP 
begin to disagree. Although the authors agree that all the models discussed in this report 
(Alzheimer‟s Mouse, Parkinson‟s Fly, AIDS Mouse, and Oncomouse) have great societal 
benefit, there was not a consensus among the authors that this benefit outweighs the suffering of 
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two of the models (AIDS Mouse and Oncomouse).  Due to the great suffering that can be  
inflicted while studying the diseases, it seems like researchers should look for a better way to 
conduct the research if at all possible.  And IACUC committees should ensure that pain killers 
and early euthenasia are used whenever possible. 
The authors agree that the patenting of transgenic animals has great potential, and 
provides a means of rewarding the companies that take the risks. However, both authors agree 
that the current patenting system is not quite developed enough for biotechnology at this point. 
Changes need to be made in the system before patents will fully unlock the potential of this 
growing field. However, the recently approved standards for FDA evaluation of genetically 
engineered animals are on the right track; one transpharmer drug (ATryn) has already been 
approved, and many more drugs will come.  It is agreed that once patenting changes have been 
made, the benefits of transgenic animal patenting will far outweigh the risks. 
 
